The miR-30c inhibitor enhanced the Notch1, NICD, HES1 and HEY1 proteins in A172 and U251 glioma cells, and shRNA-Notch1 weakened this enhancement (Fig. 8A,B). Here, HES1 is linked to central nervous system cancer.